The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead

Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead

February 20, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) recently expanded the indications for ferumoxytol injections to include the treatment of adults with iron-deficiency anemia. The agency has also received an application for GP2017, a biosimilar to adalimumab.

You Might Also Like
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
  • EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
Explore This Issue
March 2018
Also By This Author
  • FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

Ferumoxytol Injection Garners Additional FDA Approval
On Feb. 5, the FDA approved a supplemental new drug application for ferumoxytol injection (Feraheme), adding additional indications for the treatment.1 The medication’s initial FDA approval included the treatment of adults with chronic kidney disease (CKD). The new indications include treating adults with iron-deficiency anemia who cannot tolerate oral iron therapy or who have not had a satisfactory response to oral iron.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This new approval may potentially lead to a significant increase in the number of patients benefiting from ferumoxytol injections, including both CKD and non-CKD patients.

FDA Accepts Adalimumab Biosimilar Application
GP2017, from Sandoz, is a biosimilar version of AbbVie’s adalimumab (Humira).2 In 2016, adalimumab received $16.1 billion in sales worldwide. However, in November 2017, the U.S. patents for branded adalimumab expired, which also expired in Europe in June 2017.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In February, the FDA accepted an application for GP2017. The application includes pharmacokinetic study data in healthy volunteers and a Phase 3 confirmatory safety and efficacy study in patients with moderate to severe chronic plaque psoriasis (ADACCESS). An application for GP2017 was also submitted to the European Medicines Agency in June 2017.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. AMAG Pharmaceuticals. News release: AMAG Pharmaceuticals announces FDA approval of supplemental new drug application (sNDA) for Feraheme (ferumoxytol injection). 2018 Feb 5.
  2. Generics and Biosimilars Initiative (GaBI). News release: FDA accepts applications for adalimumab and trastuzumab biosimilars. 2018 Feb 2.

Filed Under: Biologics & Biosimilars, Drug Updates, Pharma Co. News Tagged With: adalimumab, anemia, Biosimilars, FDA, FDA approval, ferumoxytol, ferumoxytol injection, GP2017, Humira, iron-deficiency anemia, U.S. Food and Drug Administration (FDA)Issue: March 2018

You Might Also Like:
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
  • EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.